University College London Receives National MS Society Funding to Identify and Refine Nerve-Protecting Therapies
January 14, 2016
Researchers at the University College London and Queen Mary University (London, U.K.) have developed possible neuroprotective therapies for the treatment of neurodegenerative diseases including multiple sclerosis. With previous National MS Society funding through Fast Forward
, the team produced a compound (JW47) that was effective in a mouse model of MS. The compound targets mitochondria, the power plants inside cells whose malfunction can lead to nerve cell loss. The collaborators have received new funding from Fast Forward to refine this and other compounds to optimize their potential use in stopping or slowing progressive MS.
about this research
about the Society’s commercial research investments
about research to find solutions to progressive MS